1. Introduction {#sec1}
===============

Essential hypertension (primary hypertension or idiopathic hypertension) is the most common type of hypertension, affecting 95% of hypertensive patients. The total number of adults with hypertension in 2000 was 972 million, and the number of adults with hypertension in 2025 was predicted to increase by about 60% to a total of 1.56 billion (29.2% of the world\'s adult population) \[[@B1]\]. The etiology of primary hypertension is not fully understood. Treatment of hypertension is facing the challenge because effective therapies of hypertension are limited by availability, cost, and adverse effects. Chinese traditional medicine provides a potential option to overcome current challenge of antihypertension therapy. Chinese medicine, a system of ancient medical practice that differs in substance, methodology, and philosophy to modern medicine, plays key role in health maintenance and has become more frequently used.

CM has been used to treat symptoms related to hypertension for more than 2500 years. JHD is one of the effective formulas to combat hypertension in clinic. HJD is an ancient Chinese prescription, first reported in the text*Zh* $\check{\text{o}}$ *u H*î*u B*è*i J*í*F*ā*ng*(Emergency Standby Remedies) by Gě Hïng (281--341 CE, Jìn dynasty). This formula is commonly used for all types of Fire Toxin obstructing the three burners with high fever, irritability, and dry mouth and throat. Pharmacologic Researches of this formula show that it has antisepticised dephlogisticate and enhances the immune system functions. Our previous studies show that HJD has antihypertension effects via regulating the inflammatory factors and altering NO and SOD expression \[[@B2]\]. Here, this report is to study the pathogenic mechanism of hypertension and its effects on thoracic aorta gene expression.

2. Materials and Methods {#sec2}
========================

2.1. Animals Models and Treatment {#sec2.1}
---------------------------------

The cohorts of 6-week-old male Spontaneous Hypertensive Rats (SHRs) were randomly placed into HJD group and SHR model group. There are eight rats in each group. All rats were from Beijing Vital River Laboratory Animal Technology Co., Ltd., license Number is SCXK2006-0009, SPF, weight 160 ± 10 g. Eight 6-week-old male normotensive Wistar-Kyoto(WKY) rats were used as the normal control group that were from Experimental Animal Center of Guangxi Medical University, license Number is SCXK2006-0003, SPF, weight 160 ± 10 g.

The animals were housed in a room with 20--24°C 30--40% humidity. Rats were ad lib to food and water. This study was performed following the Guide for the Care and Use of Laboratory Animals of the P. R. China. The protocol was approved by the Committee on the Ethics of Animal Experiments of the Guangxi University of Chinese Medicine.

HJD was consisted of Rhizoma Coptidis,*Phellodendron amurense*Rupr, Radix Scutellariae, and*Gardenia jasminoides*Ellisin the ratio of 3 : 2 : 2 : 3. All the herbs were provided by Ruikang Affiliated Hospital to Guangxi University of Chinese Medicine who bought from Yulin Herb Market in unify. The purity of each component was determined to be above 98% by high-performance liquid chromatography (HPLC) analysis. HPLC-grade reagents, methanol, acetonitrile, and water were obtained from J. T. Baker (Phillipsburg, NJ, USA). These four herbs were dried in 24 h and grinded into coarse powder. The herbs were cooked into concentrated juice (1 mL juice = 2.2 g raw herb). The rats were given HJD juice at 5.4 g/(kg·d) by gavage. The control group was given 0.9% saline with the same volume. All the treatments were administrated by gavage for 6 successive weeks.

2.2. Measurement of Blood Pressure {#sec2.2}
----------------------------------

Noninvasive BP of rats was measured using the Nexfin monitor (BMEYE B.V, Amsterdam, and The Netherlands) with the latest implementation of the caudal artery method. Rats were measured for BP at day 0, 7, 14, 28, and 42 after HJD treatment each rat was measured 3 times to obtain average BP value.

2.3. RNA Isolation and Microarray Experiment {#sec2.3}
--------------------------------------------

After the last HJD administration, all rats were sacrificed and then the thoracic aortas were quickly dissected and stored in the freezer tube in −80°C for RNA extraction. Rat tissues were homogenized in Trizol (Invitrogen, Carlsbad, CA), and the total RNA was extracted using chloroform and isopropyl alcohol and purified using the RNeasy Mini Kit and RNase-free DNase Set (Qiagen, Valencia, CA) according to the manufacturers\' protocols. The quality of the extracted total RNA was measured using the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) and the Nano-Chip-protocol before microarray experiments. Gene Chip analysis was performed using the Agilent Whole Rat Genome Oligo Microarray. Labeling and hybridization were performed at Shanghai Biotechnology Corporation.

2.4. Data Analysis {#sec2.4}
------------------

Microarray data were analyzed using the SBC Analysis system (: <http://sas.ebioservice.com/index.jsp>).

Gene expression profiles of SHR were compared to those from WKY or HJD treatment group. The changing was selected by the criteria: *P* \< 0.05 and Fold Changes ≥2.

3. Results {#sec3}
==========

3.1. HJD Reduced Blood Pressure of SHR Rats {#sec3.1}
-------------------------------------------

The rat in SHR group had significantly higher blood pressures compared with normal control group before HJD treatment (*P* \< 0.05). After one week administration, the BP of HJD group began to decrease than SHR group. After 6 weeks of treatment, the rats in HJD group had almost similar blood pressure to the rats in control group ([Figure 1](#fig1){ref-type="fig"}).

3.2. Hypertension and HJD Treatment Caused Gene Expression Changes {#sec3.2}
------------------------------------------------------------------

Volcano plot that was drawn by *P* value and Fold Change checked by *t*-test showed the significant difference of sample data between chipset groups. (Figures [2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"} described by Gene-Spring 11.0: *X*-axis for Log~2~ (Fold Change), *Y*-axis for---Log~10~ (*P* value); *X*-axis parallel line: *P* = 0.05, *Y*-axis parallel line: Fold Change = 2.0; Red Zone: *P* \< 0.05; and Fold Change ≥2.0).

Gene microarray analysis showed that there were 858 genes that alter in SHR group compared with normal control groups ([Figure 2](#fig2){ref-type="fig"}). There were 417 downregulated ([Table 1](#tab1){ref-type="table"}) and there were 441 upregulated ([Table 2](#tab2){ref-type="table"}).

JHD treatment altered 96 gene expressions pared with untreated SHR group; *P* \< 0.05 and Fold Change ≥ 2.0 were identified between the HJD treatment group and the SHR model groups. Of these, 76 genes were downregulated and 20 genes were upregulated ([Table 3](#tab3){ref-type="table"}).

3.3. HJD Induced Gene Changes and Their Biological Consequences {#sec3.3}
---------------------------------------------------------------

The genes that were altered after HJD treatment mainly belong to 12 classifications ([Table 4](#tab4){ref-type="table"}) including genes that regulate immune system, cellular functions, and metabolic and developmental functions. There were 33 genes in the category of immune system development, leukocyte activation, regulation of immune system process, cell activation and proliferation, regulation of immune system process, positive regulation of biological process, and so forth (*P* \< 0.05) ([Table 5](#tab5){ref-type="table"}).

Further functional pathway analysis showed that hypertension altered genes were involved in 22 KEGG pathways ([Table 6](#tab6){ref-type="table"}), while HJD altered genes were mainly related to 10 KEGG pathways (*P* \< 0.05) ([Table 7](#tab7){ref-type="table"}).

4. Discussion and Conclusions {#sec4}
=============================

*prehypertension criterion* is systolic pressure 120\~139 mmHg (1 mmHg = 0.133 kPa) and/or diastolic pressure 80\~89 mmHg. As the important pathogenic risk factor of many cardiovascular and cerebrovascular diseases, prehypertension can affect the structure and function of heart, brain, and liver compared to the ideal blood pressure. During prehypertension, the elasticity of large artery trunks was already obviously damaged, and the relaxation function of left ventricle was slightly damaged, which are the damage symbol of target organs in hypertension \[[@B3]\]. Our previous data showed that SHR arterial elasticity and endothelial functions in SHR rats were impaired in early stage \[[@B3]\]. And the gene array studies coincidences showed that multiple genes in aorta thoracic in young SHR were changed in transcription level compared with normotensive WKY. In particular, expression genes related to smooth muscles shrink or cytoskeletons were significantly increased or decreased. These genes were Chrm3, MRPS2, TRPC4, P2rx4, Slc8a3, Htr5a, Chp, and so forth. The muscarinic cholinergic receptor 3, also known as Chrm3 (FC = 4.343), controls smooth muscle contraction and its stimulation causes secretion of glandular tissue \[[@B4]\]. MRPS2 (FC = 0.081) encodes mitochondrial ribosomal protein S2 \[[@B5], [@B6]\]. Genes related to Calcium signaling pathway, like TRPC4(FC = 13.374), P2rx2 (FC = 4.075), and P2rx4 (FC = 3.329) expression, increased, whereas Slc8a3 (FC = 0.313), Htr5a (FC = 0.332), and Chp (FC = 0.398) expression decreased, which will cause the imbalance of Ca(2+) in endothelial cells. TRPC4 is well recognized as a prominent Cation channel in the vascular endothelium, which suggested to serve stimulated Ca(2+) entry in a specific endothelial state during the transition from a proliferating to a quiescent phenotype. Thus, TRPC4 may adopt divergent, as yet unappreciated functions in endothelial Ca(2+) homeostasis and emerges as a potential key player in endothelial phenotype switching and tuning of cellular growth factor signaling \[[@B7]\]. P2X receptors are ATP activated channels that allow the passage of ions across cell membranes and participate in regulating renal microvascular function, autoregulation, and hypertension-associated renal vascular injury \[[@B8]\].

The ATP-gated P2X4 ion channel, expressed on endothelial cells and encoded by P2rx4 gene, is crucial to flow-sensitive mechanisms that regulate blood pressure and vascular remodeling. P2rx4 (−/−) mice do not have normal endothelial cell responses to flow, such as influx of Ca(2+) and subsequent production of the potent vasodilator nitric oxide (NO). Additionally, vessel dilation induced by acute increases in blood flow is markedly suppressed in P2rx4 (−/−) mice. Furthermore, P2rx4 (−/−) mice have higher blood pressure and excrete smaller amounts of NO products in their urine than wild-type mice do. Moreover, no adaptive vascular remodeling, that is, a decrease in vessel size in response to a chronic decrease in blood flow, was observed in P2rx4 (−/−) mice \[[@B9]\]. SLC8A3, solute carrier family 8 (sodium/calcium exchanger) members 3, encodes a member of the sodium/calcium exchanger integral membrane protein family. Three mammalian isoforms in family 8 (SLC8A1, SLC8A2, and SLC8A3) and their splice variants are expressed in a tissue-specific manner to mediate Ca(2+) fluxes across the cell membrane and, thus, significantly contribute to maintain Ca(2+) homeostasis in a wide variety of cell types \[[@B10]\]. The gene described in this record is a member of 5-hydroxytryptamine receptor family and encodes a multipass membrane protein that functions as a receptor for 5-hydroxytryptamine and couples to G proteins, negatively influencing cAMP levels via GI and Go \[[@B11]\]. This protein has been shown to function in part through the regulation of intracellular Ca(2+) mobilization \[[@B12]\]. Calcium binding protein p22 (Chp), which belongs to the EF-hand superfamily of Ca(2+)-binding proteins, may act by transducing cellular Ca(2+) signals to downstream effectors in many cell types \[[@B13]\]. It is also known to be an endogenous inhibitor of calcineurin activity \[[@B14]\] and thus inactivates the T cells of the immune system. Prehypertension showed the symptoms of dizziness, headache, anxiety, and irritability \[[@B15]\]. 300 cases of prehypertension were investigated \[[@B16]\] on TCM syndrome on the criterion of*Subhealth of TCM clinical guidelines* which was announced in 2006. The results showed that most of the cases were belonging to patterns of depression of the liver generating pathogenic fire, stagnation of liver qi and spleen deficiency, and interior disturbance of phlegm heat.

HJD were first reported in Gehong\' book of*Handbook of Prescription for Emergency*, but it did not give the name of this prescription; however, the first name SLC8A3, solute carrier family 8 (sodium/calcium exchanger) members 3, encodes a member of the sodium/calcium exchanger integral membrane protein family. Three mammalian isoforms in family 8 (SLC8A1, SLC8A2, and SLC8A3) and their splice variants are expressed in a tissue-specific manner to mediate Ca(2+) fluxes across the cell membrane and, thus, significantly contribute to maintain Ca(2+) homeostasis in a wide variety of cell types \[[@B10]\]. The gene described in this record is a member of 5-hydroxytryptamine receptor family and encodes a multipass membrane protein that functions as a receptor for 5-hydroxytryptamine and couples to G proteins, negatively influencing cAMP levels via GI and Go \[[@B11]\]. This protein has been shown to function in part through the regulation of intracellular Ca(2+) mobilization \[[@B12]\]. Calcium binding protein p22 (Chp), which belongs to the EF-hand superfamily of Ca(2+) binding proteins, may act by transducing cellular Ca(2+) signals to downstream effectors in many cell types \[[@B13]\]. It is also known to be an endogenous inhibitor of calcineurin activity \[[@B14]\] and thus inactivates the T cells of the immune system. Prehypertension showed the symptoms of dizziness, headache, anxiety, and irritability \[[@B15]\]. 300 cases of prehypertension were investigated \[[@B16]\] on TCM syndrome on the criterion of*Subhealth of TCM clinical guidelines* which was announced in 2006. The results showed that most of the cases were belonging to patterns of depression of the liver generating pathogenic fire, stagnation of liver qi and spleen deficiency, and interior disturbance of phlegm heat.

HJD were first reported in Gehong\' book of*Handbook of Prescription for Emergency*, but it did not give the name of this prescription; however, the first name occurred in Wangtao\' book of*Waitaimiyao*. This prescription was made up of Rhizoma Coptidis,*Phellodendron amurense* Rupr, Radix Scutellariae, and*Gardenia jasminoides* Ellis in proportion. Rhizoma Coptidis exerts as the sovereign to purge heart fire and middle energizers fire;*Phellodendron amurense* Rupr works as the minister to clear away lung heat and the upper energizers fire. Radix Scutellariae clears away the lower energizers fire and*Gardenia jasminoides* Ellis clears away the triple energizers fire. They work together to remove the toxin. HJD have played more and more important role in cardiovascular diseases that have already used HJD in treatment of hypertension in clinic for many years.

Hypertension induces endothelial dysfunction resulting in impairment of endothelium-dependent vasodilatation and widespread abnormalities in endothelial integrity and homeostasis \[[@B17]\]. Endothelial dysfunction exhibits several pathological conditions, including altered anticoagulant and anti-inflammatory properties of the endothelium, impaired modulation of vascular growth, and dysregulation of vascular remodeling. The major cause of impairment of endothelium-dependent vasorelaxation is loss of nitric oxide (NO) bioactivity in the vessel wall \[[@B18]\].

Our previous studies showed that\' spontaneous hypertension rats\' blood pressure increases at six-week-old age, and the tail-arterial-systolic-pressure increase at 12-weeksof age. Hypertension decreases plasma NO and SOD, and increase of MDA and Von Wille brand factor (vWF) at the 12 weeks of age. HJD treatment significantly reversed hypertension-induced NO and SOD \[[@B2]\].

HJD treatment altered many genes related to cell response processes, hyperplasia, and immune response, such as IL1b(FC = 2.519), Klrk1(FC = 2.001), Snca(FC = 2.665), and Gch1(FC = 2.164). It has been reported that interleukin (IL)-1 beta induces the synthesis of both nitric oxide (NO) and prostaglandin (PG)E2 in cultures of dispersed ovarian cells and exerts cytotoxic effects on these cells \[[@B19], [@B20]\]. Furthermore, IL-1 beta can interact with NO and PGE2 during steroid genesis \[[@B21]\]. Klrk1 is involved in positive regulation of nitrogen compound metabolic process (*Gene Ontology*:*0051173*). Alpha-synuclein (ASN), encoded by Snca gene, is a small soluble acidic protein and plays an important role in the regulation of synaptic nerve terminal function. It has been shown that ASN stimulated NOS activity and NO release in the rat brain \[[@B22]\]. GTP cyclohydrolase 1 (GCH1) is the first and rate-limiting enzyme in the synthesis of tetrahydrobiopterin (BH4), an essential cofactor for tyrosine hydroxylase (TH) and NOS in the catecholamine and NO production pathways, respectively, thus playing a crucial role in the sympathoadrenal and endogenous nitro vasodilator systems \[[@B23]\].

According to the GO analyses, compared with normotensive WKY, the biological procedure which SHR differential expression genes attended mainly focused on 6 items of secondary classification, such as multicellular organismal process, developmental process, multiorganism process, response to stimulus, anatomical structure formation, and regulation of biological process, mainly involving 12 items of third classification, for example, ossification, response to other organism, regulation of multicellular organismal process, regulation of developmental process, interspecies interaction between organisms, tissue remodeling, response to biotic stimulus, and so froth (*P* \< 0.05) ([Table 5](#tab5){ref-type="table"}).

HJD can upregulate NO expression in the blood plasma \[[@B4]\]. Here HJD also altered the NO pathway related genes including IL1b, Klrk1, Snca, and Gch1. Taking together, these findings suggest that HJD may reduce hypertension by regulating NO pathways.

In conclusion, HJD can significantly reduce hypertension and alter the gene profiles in aorta thoracic in rats. These results provide the potential gene changes and pathways underlying hypertension and antihypertension effects of HJD in treatment of hypertension.
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![Effects of HJD on blood pressure in rats. BP of rat was measured with mmHg unit. There were 8 rats in each group. \**P* \< 0.05 versus SHR group.](ECAM2014-565784.001){#fig1}

![Hypertension induced gene changes compared with normal control rats. Note: model = spontaneous hypertension rats (SHR) model group, and control = normotensive Wistar-Kyoto rats control group.](ECAM2014-565784.002){#fig2}

![HJD treatment caused gene changes compared with untreated SHR rats versus SHR. Note: model = spontaneous hypertension rats (SHR) model group; medication = HJD treatment group.](ECAM2014-565784.003){#fig3}

###### 

Downregulated genes in hypertension rats.

  Gene                                                                           Abbr.    Gene Id   Chro.   FC      *P*
  ------------------------------------------------------------------------------ -------- --------- ------- ------- --------------
  DRABUB01 rat DRG library Rattus norvegicus cDNA clone DRABUB01 5′              ---      NA        9       0.097   3.86*E* − 03
  Similar to RIKEN cDNA 1700001F09 (LOC289957)                                   ---      NA        15      0.092   9.47*E* − 05
  Mitochondrial ribosomal protein S2                                             Mrps2    362094    3       0.081   6.49*E* − 03
  Q99LR9_MOUSE (Q99LR9) Riok3 protein (fragment), partial (13%)                  ---      NA        18      0.079   6.79*E* − 04
  AGENCOURT_26625193 NIH_MGC_253 Rattus norvegicus cDNA clone IMAGE:7304073 5′   ---      NA        5       0.054   6.58*E* − 03
  Similar to 60S ribosomal protein L19 (LOC316856)                               ---      NA        Un      0.053   1.40*E* − 04
  Solute carrier family 4 (anion exchanger), member 1                            Slc4a1   24779     10      0.051   8.24*E* − 03
  Cell division cycle 25 homolog A (S. pombe)                                    Cdc25a   171102    8       0.039   6.88*E* − 04
  Synuclein, alpha (non-A4 component of amyloid precursor)                       Snca     29219     4       0.029   6.00*E* − 03
  Unknown                                                                        ---      NA        7       0.028   2.12*E* − 04
  Coproporphyrinogen oxidase                                                     Cpox     304024    11      0.021   2.11*E* − 06
  AGENCOURT_70342463 NIH_MGC_368 Rattus norvegicus cDNA clone IMAGE:8376762 5′   ---      NA        1       0.013   9.98*E* − 03
  Q8FIR6_ECOL6 (Q8FIR6) cytochrome b561 homolog 2, partial (5%)                  ---      NA        9       0.009   2.05*E* − 04
  UI-R-C3-sf-g-04-0-UI                                                           ---      NA        1       0.007   6.28*E* − 03

Note. Abbr.: gene abbreviation, Chro.: chromosome, Gene Id represents the identity (ID) of the gene in GenBank; FC = SHR model group gene expression level/normotensive WKY control group expression level. "---/NA/Un" indicates unknown.

###### 

Upregulated genes (model versus control).

  Gene                                                                                                                      Abbr.       Gene Id   Chro.   FC       *P*
  ------------------------------------------------------------------------------------------------------------------------- ----------- --------- ------- -------- --------------
  Bone gamma-carboxyglutamate (gla) protein                                                                                 Bglap       25295     2       61.402   1.96*E* − 03
  Uncharacterized protein                                                                                                   ---         NA        2       25.856   1.96*E* − 05
  Unknown                                                                                                                   ---         NA        13      24.949   9.99*E* − 03
  Cellular retinoic acid binding protein 2                                                                                  Crabp2      29563     2       20.657   4.73*E* − 03
  Major histocompatibility complex, assembled from 40 BACs, strain Brown Norway (BN/ssNHsd), RT1n haplotype; segment 2/11   ---         NA        20      19.648   1.52*E* − 03
  V-set domain containing T cell activation inhibitor 1                                                                     Vtcn1       295322    2       18.951   1.15*E* − 03
  Interferon-induced protein with tetratricopeptide repeats 1                                                               Ifit1       56824     1       17.991   1.51*E* − 04
  Unknown                                                                                                                   ---         NA        10      13.875   5.54*E* − 03
  Uncharacterized protein                                                                                                   ---         NA        1       13.621   5.06*E* − 04
  Similar to SMAD-interacting zinc finger protein 2                                                                         LOC679126   679126            13.572   8.21*E* − 05
  Transient receptor potential cation channel, subfamily C, member 4                                                        Trpc4       84494     2       13.374   8.20*E* − 04
  Q3X0T1_9ACTN (Q3X0T1) 60 kDa innermembrane protein, partial (6%)                                                          ---         NA        19      12.417   4.35*E* − 03
  CJ032_MOUSE (Q9CRC6) protein C10orf32 homolog, partial (15%)                                                              ---         NA        1       11.726   8.63*E* − 04
  TL0ACA45YL24                                                                                                              ---         NA        X       11.407   1.80*E* − 03

Note. Abbr.: gene abbreviation, Chro.: chromosome, Gene Id represents the identity (ID) of the gene in GenBank; FC = SHR model group gene expression level/normotensive WKY control group expression level. "---/NA/Un" indicates unknown.

###### 

The upregulated and downregulated genes after the treatment of HLJDD.

  Gene                                                                   Abbr.     Gene Id   Chro.   FC      *P*
  ---------------------------------------------------------------------- --------- --------- ------- ------- --------------
  Solute carrier family 4 (anion exchanger), member 1                    Slc4a1    24779     10      3.871   6.74*E* − 03
  Protein phosphatase 1, regulatory subunit 3D                           Ppp1r3d   689995    3       2.566   2.78*E* − 03
  Ribonucleotide reductase M2                                            Rrm2      362720    6       2.551   6.30*E* − 03
  pim-1 oncogene                                                         Pim1      24649     20      2.529   5.12*E* − 03
  Spectrin, beta, erythrocytic                                           Sptb      314251    6       2.470   4.66*E* − 03
  Transmembrane and coiled-coil domain family 2                          Tmcc2     305095    13      2.444   3.38*E* − 03
  Unknown                                                                ---       NA        3       2.264   7.87*E* − 03
  UI-R-C4-alc-g-09-0-UI                                                  ---       NA        Un      0.235   3.60*E* − 03
  UI-R-BJ2-bql-b-07-0-UI                                                 ---       NA        13      0.385   3.14*E* − 03
  Potassium voltage-gated channel, subfamily H (eag-related), member 1   Kcnh1     65198     13      0.393   9.98*E* − 03
  Nuclear receptor subfamily 4 group A member 3                          Nr4a3     58853     5       0.456   9.87*E* − 03

Note. Abbr.: gene abbreviation, Chro.: chromosome, Gene Id represents the identity (ID) of the gene in GenBank; FC = HLJDT treatment group/SHR model group gene expression level. "---/NA/Un" indicates unknown.

###### 

Functional catalogers of hypertension-induced gene change profiles.

  GO Id        Term                                             Hit genes   *P*
  ------------ ------------------------------------------------ ----------- --------
  GO:0032501   Multicellular organismal process                              
  GO:0051239   Regulation of multicellular organismal process   56          0.0033
  GO:0048771   Tissue remodeling                                14          0.0068
  GO:0001816   Cytokine production                              15          0.0243
  GO:0003008   System process                                   77          0.0485
  GO:0032502   Developmental process                                         
  GO:0001503   Ossification                                     18          0.0005
  GO:0050793   Regulation of developmental process              66          0.0045
  GO:0051704   Multiorganism process                                         
  GO:0051707   Response to other organism                       23          0.0026
  GO:0044419   Interspecies interaction between organisms       7           0.0059
  GO:0050896   Response to stimulus                                          
  GO:0009607   Response to biotic stimulus                      24          0.0074
  GO:0042221   Response to chemical stimulus                    97          0.0214
  GO:0010926   Anatomical structure formation                                
  GO:0022607   Cellular component assembly                      41          0.042
  GO:0050789   Regulation of biological process                              
  GO:0051239   Regulation of multicellular organismal process   56          0.0033
  GO:0050793   Regulation of developmental process              66          0.0045
  GO:0048518   Positive regulation of biological process        86          0.0361

###### 

Functional category of HJD-induced gene change profiles.

  GO Id        Term                                                      Hit genes   *P*
  ------------ --------------------------------------------------------- ----------- --------
  GO:0002376   Immune system process                                                  
  GO:0002520   Immune system development                                 10          0.0001
  GO:0045321   Leukocyte activation                                      12          0.0001
  GO:0002682   Regulation of immune system process                       12          0.0001
  GO:0006955   Immune response                                           10          0.0003
  GO:0002684   Positive regulation of immune system process              7           0.0006
  GO:0045058   T cell selection                                          2           0.0046
  GO:0002253   Activation of immune response                             3           0.026
  GO:0009987   Cellular process                                                       
  GO:0001775   Cell activation                                           13          0.0001
  GO:0008283   Cell proliferation                                        15          0.0001
  GO:0048522   Positive regulation of cellular process                   22          0.0002
  GO:0008219   Cell death                                                13          0.0016
  GO:0048523   Negative regulation of cellular process                   16          0.0086
  GO:0016043   Cellular component organization                           19          0.0181
  GO:0007049   Cell cycle                                                7           0.0453
  GO:0008152   Metabolic process                                                      
  GO:0009058   Biosynthetic process                                      28          0.0005
  GO:0009893   Positive regulation of metabolic process                  11          0.0361
  GO:0006807   Nitrogen compound metabolic process                       5           0.0413
  GO:0019748   Secondary metabolic process                               2           0.0423
  GO:0032502   Developmental process                                                  
  GO:0050793   Regulation of developmental process                       17          0.0008
  GO:0051093   Negative regulation of developmental process              10          0.0026
  GO:0048856   Anatomical structure development                          21          0.0086
  GO:0009790   Embryonic development                                     8           0.0154
  GO:0007275   Multicellular organismal development                      20          0.0249
  GO:0001503   Ossification                                              4           0.0251
  GO:0009653   Anatomical structure morphogenesis                        12          0.0409
  GO:0016265   Death                                                                  
  GO:0008219   Cell death                                                13          0.0016
  GO:0032501   Multicellular organismal process                                       
  GO:0001816   Cytokine production                                       7           0.0003
  GO:0051240   Positive regulation of multicellular organismal process   7           0.0017
  GO:0051239   Regulation of multicellular organismal process            14          0.0021
  GO:0007275   Multicellular organismal development                      20          0.0249
  GO:0050896   Response to stimulus                                                   
  GO:0006955   Immune response                                           10          0.0003
  GO:0009605   Response to external stimulus                             11          0.0084
  GO:0009607   Response to biotic stimulus                               6           0.0201
  GO:0048584   Positive regulation of response to stimulus               5           0.0209
  GO:0048585   Negative regulation of response to stimulus               3           0.0445
  GO:0050789   Regulation of biological process                                       
  GO:0002682   Regulation of immune system process                       12          0.0001
  GO:0048518   Positive regulation of biological process                 24          0.0001
  GO:0050793   Regulation of developmental process                       17          0.0008
  GO:0051239   Regulation of multicellular organismal process            14          0.0021
  GO:0048519   Negative regulation of biological process                 18          0.0045
  GO:0032844   Regulation of homeostatic process                         3           0.045
  GO:0048518   Positive regulation of biological process                 24          0.0001
  GO:0048519   Negative regulation of biological process                 18          0.0045
  GO:0010926   Anatomical structure formation                            12          0.0254

###### 

Hypertension altered genes in 22 KEGG pathways.

  KEGG pathway                                             Hit genes   *P*
  -------------------------------------------------------- ----------- --------
  Olfactory transduction                                   29          0
  Neuroactive ligand-receptor interaction                  13          0.0002
  Cytokine-cytokine receptor interaction                   10          0.0009
  Focal adhesion                                           9           0.0009
  Tight junction                                           6           0.0061
  RIG-I-like receptor signaling pathway                    4           0.0081
  Ether lipid metabolism                                   3           0.0083
  Calcium signaling pathway                                7           0.0086
  Leishmania infection                                     4           0.0089
  Amyotrophic lateral sclerosis (ALS)                      4           0.0113
  Arrhythmogenic right ventricular cardiomyopathy (ARVC)   4           0.014
  ABC transporters                                         3           0.0171
  Aldosterone-regulated sodium reabsorption                3           0.0213
  Hypertrophic cardiomyopathy (HCM)                        4           0.0231
  Dilated cardiomyopathy                                   4           0.0247
  Glycosphingolipid biosynthesis---ganglio series          2           0.0265
  Glutathione metabolism                                   3           0.0284
  Apoptosis                                                4           0.032
  Wnt signaling pathway                                    5           0.0324
  Natural killer cell mediated cytotoxicity                5           0.0339
  Maturity onset diabetes of the young                     2           0.0415
  MAPK signaling pathway                                   7           0.047

###### 

HJD altered genes in 10 KEGG pathways.

  KEGG pathway                                Hit genes   *P*
  ------------------------------------------- ----------- --------
  Hematopoietic cell lineage                  3           0.0004
  Metabolic pathways                          8           0.0016
  Natural killer cell mediated cytotoxicity   3           0.0027
  NOD-like receptor signaling pathway         2           0.0066
  Cytokine-cytokine receptor interaction      3           0.0105
  Pyrimidine metabolism                       2           0.0148
  T cell receptor signaling pathway           2           0.0192
  Axon guidance                               2           0.0254
  Jak-STAT signaling pathway                  2           0.0308
  Purine metabolism                           2           0.0379

[^1]: Academic Editor: Samra Bashir
